WHANIN PHARM CO.,LTD Q3 report: revenue KRW 71.6 billion, operating profit KRW 7.5 billion
WAI summary · Not investment advice
Hwanin Pharm sold KRW 71.6 billion worth in Q3 and earned KRW 7.5 billion from its main business, up 111.8% from a year earlier and down 4.6% from the prior quarter.
Operating profit · 3 months
KRW 7.5 billion
Key facts
- Revenue (3 months)
- KRW 71.6 billion
- Net income (3 months)
- KRW 6.5 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 65.7 billion
- Revenue (year to date)
- KRW 214.2 billion
- Operating profit (prior-year 3 months)
- KRW 3.6 billion
- Operating profit (year to date)
- KRW 24.8 billion
- Net income (prior-year 3 months)
- KRW 3.3 billion
- Net income (year to date)
- KRW 21.7 billion
Commentary
AI commentary · Not investment advice
What happened
Hwanin Pharmaceutical filed its quarterly report for the third quarter of 2026. On a consolidated basis, sales for the 3 months were KRW 715.6 billion. That is up 8.9% from the same 3 months a year earlier and up 0.2% from the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the 3 months was KRW 75.3 billion. It rose 111.8% from a year earlier and fell 4.6% from the previous quarter. Net income (the final profit after taxes and other costs) was KRW 64.9 billion. It rose 98.1% from a year earlier and fell 15.7% from the previous quarter.
What changes for shareholders
For the year to date, from January 1 to September 30, sales were KRW 2,141.6 billion. Operating profit was KRW 248.0 billion. Net income was KRW 216.5 billion.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist